At BIO 2026, leading cell and gene therapy companies Kriya, Opus, and Epicrispr have revealed their innovative applications of artificial intelligence in manufacturing processes. This strategic integration of AI technologies aims to enhance operational efficiency, reduce production times, and improve product quality, addressing the increasing demand for advanced therapies.
The context of this development highlights a significant shift in the biopharmaceutical landscape, where traditional manufacturing methods are being augmented by digital solutions. As regulatory pressures mount and the complexity of therapies increases, the adoption of AI is becoming essential for companies looking to maintain competitiveness and ensure compliance with stringent quality standards.
The implications of these advancements are profound, suggesting a future where AI-driven manufacturing could lead to more personalized and effective treatments. As these companies continue to refine their processes, stakeholders across the pharma B2B spectrum—particularly in regulatory, QA/QC, and CMC sectors—must stay informed on these technological trends to align their strategies accordingly.
Open the full market picture for your next decision →
